Search - tctmd.com

Displaying 1 - 20 of 47

Sort: Relevancy | Date

News Industry News

Two Differing Blood Clot Prevention Medications Used During Heart Procedure Are Both Safe and Effective for Patients, New Study Finds

November 21, 2016

News Industry News

Armetheon Announces Positive Results of Pharmacokinetics Study of Tecarfarin versus Warfarin

August 25, 2016

News Industry News

CorMatrix® Cardiovascular, Inc. Treats First Patient in Its US Clinical Study for CorMatrix® ECM® Tricuspid Valve at Franciscan St. Francis Health Indianapolis, IN

March 17, 2016

News Industry News

Meta-Analysis of AGGRASTAT® (Tirofiban HCl) Presented at CRT 2016 Conference

February 22, 2016

News Industry News

Real-World Data Confirms Safety and Efficacy Profile of XARELTO®, With Shorter Hospital Stays, for the Treatment of Deep Vein Thrombosis

December 07, 2015

News Industry News

Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate)

November 29, 2015

News Industry News

Boston Scientific Receives CE Mark For Next Generation WATCHMAN FLX™ Left Atrial Appendage Closure Device

November 19, 2015

News Industry News

Similar Results With Bivalirudin Compared With Heparin Anticoagulation In TAVR Patients

October 15, 2015

News Industry News

Scripps experts present at 2015 TCT scientific symposium

October 09, 2015

News Industry News

CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa®)

September 25, 2015

News Industry News

CeloNova Announces FDA Approval to Start a Randomized Trial for the COBRA PzF™ Coronary Stent System

September 21, 2015

News Industry News

Portola Pharmaceuticals Announces Second Part of Phase 3 ANNEXA(TM)-R Study: Andexanet Alfa and Rivaroxaban Meets Primary and Secondary Endpoints

September 16, 2015

News Industry News

Acute Pulmonary Embolism Trial (SEATTLE II) Published in the JACC: Cardiovascular Interventions

August 24, 2015

News Industry News

ACC prepares to launch two afib-related registry programs

August 14, 2015

News Industry News

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

July 29, 2015

News Industry News

Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin C

June 25, 2015

News Industry News

Idarucizumab Reverses the Anticoagulant Effect of Dabigatran Within Minutes in Patient Study

June 22, 2015

News Industry News

Terumo Launches The MISAGO® RX Self-Expanding Peripheral Stent To U.S. Market

June 18, 2015

News Industry News

One-Year Outcomes Data on Stroke Prevention in Patients With Newly Diagnosed Atrial Fibrillation (AF) to Be Presented at ISTH 2015

June 18, 2015

News Industry News

Patients Undergoing Catheter Ablation Presented at Heart Rhythm 2015

May 15, 2015

Advertisement

Two Differing Blood Clot Prevention Medications Used During Heart Procedure Are Both Safe and Effective for Patients, New Study Finds

Armetheon Announces Positive Results of Pharmacokinetics Study of Tecarfarin versus Warfarin

CorMatrix® Cardiovascular, Inc. Treats First Patient in Its US Clinical Study for CorMatrix® ECM® Tricuspid Valve at Franciscan St. Francis Health Indianapolis, IN

Meta-Analysis of AGGRASTAT® (Tirofiban HCl) Presented at CRT 2016 Conference

Real-World Data Confirms Safety and Efficacy Profile of XARELTO®, With Shorter Hospital Stays, for the Treatment of Deep Vein Thrombosis

Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate)

Boston Scientific Receives CE Mark For Next Generation WATCHMAN FLX™ Left Atrial Appendage Closure Device

Similar Results With Bivalirudin Compared With Heparin Anticoagulation In TAVR Patients

Scripps experts present at 2015 TCT scientific symposium

CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa®)

CeloNova Announces FDA Approval to Start a Randomized Trial for the COBRA PzF™ Coronary Stent System

Portola Pharmaceuticals Announces Second Part of Phase 3 ANNEXA(TM)-R Study: Andexanet Alfa and Rivaroxaban Meets Primary and Secondary Endpoints

Acute Pulmonary Embolism Trial (SEATTLE II) Published in the JACC: Cardiovascular Interventions

ACC prepares to launch two afib-related registry programs

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin C

Idarucizumab Reverses the Anticoagulant Effect of Dabigatran Within Minutes in Patient Study

Terumo Launches The MISAGO® RX Self-Expanding Peripheral Stent To U.S. Market

One-Year Outcomes Data on Stroke Prevention in Patients With Newly Diagnosed Atrial Fibrillation (AF) to Be Presented at ISTH 2015

Patients Undergoing Catheter Ablation Presented at Heart Rhythm 2015

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content